All News
Is there an association btwn ⬆️ CRP & cardiovascular dysfunction in #axSpA?
🔹️245 pts
🔹️CRP recorded for past 5y
🔹️sustained high CRP in 40%
🔹️associated with ⬆️ cardiovascular risk factors, ⬇️endothelial function & subclin atheroslerosis
POS0714
#EULAR2025
@RheumNow https://t.co/jAlj3sr95H
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Management of AAV:
1.High dose GC f/b reduced dose taper ‼️caution in pts w/severe renal dz and RTX induction.
2. RTX effective for induction and maintenance, best for relapses.
3.PLEX: in RPGN pts if accesible ⚠️ risk for infection.
4.Avacopan: for faster GC weaning. No https://t.co/kfZ4gM38KG
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Pearls on EGPA:
1. GC are mainstay for mild
dz
2. Organ threatening/relapsing➡️CYP (RTX alternative)
3. W/o organ threatening➡️ anti-IL-5/IL-5R.
4. IL5i are less effective for ENT
5. Consider sx for nasal polyps.
#EULAR2025 @RheumNow https://t.co/zoJEWxafsN
Links:
Adela Castro AdelaCastro222 ( View Tweet)
EULAR FMF recommendations 2025:
still emphasis on colchicine adherence to maximal dose
+/- bDMARDs if needed for control
+/- csDMARDs for residual chronic MSK involvement
new: consider tapering bDMARD if remission >6mo
See the treatment algorithm below⬇️
#EULAR2025 @RheumNow https://t.co/Hy6DOKzfUL
Links:
David Liew drdavidliew ( View Tweet)
Key summary slide of research in the use of CD19 CAR T cells in rheumatology indications
Dinesh Khanna @RheumNow #EULAR2025 https://t.co/CoFHqaE1L1
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Despite the evolution of anti-synthetase antibodies, there’s a clear need for better ways to define the disease.
Enter the ACR/EULAR CLASS initiative - classification criteria for anti-synthetase syndrome
⬇️ see the next tweet
#EULAR2025 @RheumNow https://t.co/Z3rPOt1vlx
Links:
David Liew drdavidliew ( View Tweet)
FMF #Recommendations
🔺️Start Colchicine in All (& continue for confirmed pts)
🔺️Single or divided dose, depend on adherence & tolerance
🔺️Max dose 2 mg children, 3 mg adults
🔺️if failure: add IL1i (6 RCT) (2 for IL6i)
🔺️Add c or bDMARd if MSK
#EULAR2025
@RheumNow https://t.co/fPyQrLbb6S
Nelly ZIADE 🍀 Nellziade ( View Tweet)
FMF #Recommendations
During attack:
🔺️No use of increasing Colchicine
🔺️No use for corticosteroids and opioid
🔺️Use NSAIDs
#EULAR2025
@RheumNow https://t.co/jJjWJra7yr
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Autologous CAR T cell production, administration and monitoring
Dinesh Khanna @RheumNow #EULAR2025 https://t.co/zrXjxSCRgl
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
EULAR/ACR Classification Criteria for #ASyS, the new acronym of Antisynthetase Syndrome
🔺️Do not apply if patient is positive for other antibodies like SSA
#EULAR2025
@RheumNow https://t.co/AD5tTipBtt
Nelly ZIADE 🍀 Nellziade ( View Tweet)
FMF #Recommendations
#Colchicine can be fatal
🔺️Monitor regularly
#EULAR2025
@RheumNow https://t.co/VJZYPaBrvE
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Why do people not respond to psoriatic arthritis therapies?
#EULAR2025 @RheumNow https://t.co/VGLN0R3TyY
David Liew drdavidliew ( View Tweet)
What is the difference between difficult to treat, and treatment-refractory?
(see these criteria for PsA)
Treatment refractory means that co-morbidities, psychosocial issues and other factors have been managed adequately, but inflammation keeps on going
#EULAR2025 @RheumNow https://t.co/Fzpf0eiCWY
David Liew drdavidliew ( View Tweet)
FMF #Recommendations
#Colchicine can be fatal
🔺️Beware of drug interactions
🔺️Mostly statins in adults
🔺️Macrolides in children
#EULAR2025
@RheumNow https://t.co/SYGLpAJXFu
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Joint pain and fatigue are actually the biggest issues for people living with haemochromatosis, but we in rheumatology don’t have organized care for them.
A call to action from Patrick Kiely, to do better by these patients
#EULAR2025 @RheumNow https://t.co/h3Zvov642L
David Liew drdavidliew ( View Tweet)
Manifestations of relapsing polychondritis
@Lupusreference @RheumNow #EULAR2025 https://t.co/EuPOdKKjax
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
The ‘iron fist’ of haemochromatosis arthropathy, and other key features:
Patrick Kiely #EULAR2025 @RheumNow https://t.co/grs1Tq3GAk
Links:
David Liew drdavidliew ( View Tweet)
Which CAR-based strategies would you consider to treat severe refractory #SLE based on data presented at #EULAR2025? @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
POETYK PsA-1
Deucravacitinib TYK2i RCT Ph 3
ACR 20 DEU 54% vs. 34% PBO wk 16
ACR 50 DEU 23% vs. 14% PBO
also significant diff for HAQ-DI PASI 75 SF-36 PCS and MDA
Less Rx progression
@RheumNow #EULAR2025 LB0001 https://t.co/oRLlHwI4Bh
Aurelie Najm AurelieRheumo ( View Tweet)
Why do we need RA treatment recommendation updates? We keep on getting new data, for our keystone disease
so today Josef Smolen and colleagues present the new 2025 EULAR recommendations
#EULAR2025 @RheumNow https://t.co/OdHL8CAIKv
David Liew drdavidliew ( View Tweet)
